IRIS
CALCAGNO, Andrea
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 5.279
NA - Nord America 4.217
AS - Asia 3.484
SA - Sud America 637
AF - Africa 624
Continente sconosciuto - Info sul continente non disponibili 386
OC - Oceania 9
Totale 14.636
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.917
RU - Federazione Russa 2.326
NL - Olanda 1.877
SG - Singapore 1.308
CN - Cina 1.002
BJ - Benin 471
BR - Brasile 406
VN - Vietnam 337
FR - Francia 336
BD - Bangladesh 304
IT - Italia 245
CA - Canada 139
DE - Germania 131
IN - India 114
HK - Hong Kong 100
MX - Messico 94
GB - Regno Unito 84
AR - Argentina 82
IE - Irlanda 63
ZA - Sudafrica 54
SE - Svezia 46
ID - Indonesia 41
IQ - Iraq 41
ES - Italia 40
PL - Polonia 34
TR - Turchia 32
CO - Colombia 30
EC - Ecuador 29
CL - Cile 25
JP - Giappone 24
SA - Arabia Saudita 24
UA - Ucraina 23
VE - Venezuela 21
KE - Kenya 18
DZ - Algeria 16
JM - Giamaica 16
PE - Perù 16
PK - Pakistan 16
MA - Marocco 14
PY - Paraguay 14
PH - Filippine 13
AZ - Azerbaigian 11
JO - Giordania 11
EG - Egitto 10
KR - Corea 10
AU - Australia 9
BB - Barbados 9
PT - Portogallo 9
UZ - Uzbekistan 9
RS - Serbia 8
TN - Tunisia 8
TW - Taiwan 8
HU - Ungheria 7
KZ - Kazakistan 7
NP - Nepal 7
OM - Oman 7
SY - Repubblica araba siriana 7
AE - Emirati Arabi Uniti 6
BO - Bolivia 6
ET - Etiopia 6
MY - Malesia 6
SN - Senegal 6
TH - Thailandia 6
UY - Uruguay 6
BE - Belgio 5
BG - Bulgaria 5
CZ - Repubblica Ceca 5
IL - Israele 5
LT - Lituania 5
LV - Lettonia 5
PS - Palestinian Territory 5
RO - Romania 5
TT - Trinidad e Tobago 5
CR - Costa Rica 4
HN - Honduras 4
NI - Nicaragua 4
PR - Porto Rico 4
XK - ???statistics.table.value.countryCode.XK??? 4
CH - Svizzera 3
CI - Costa d'Avorio 3
DO - Repubblica Dominicana 3
FI - Finlandia 3
GT - Guatemala 3
LB - Libano 3
PA - Panama 3
BM - Bermuda 2
BY - Bielorussia 2
CG - Congo 2
CY - Cipro 2
GE - Georgia 2
GR - Grecia 2
GY - Guiana 2
KG - Kirghizistan 2
KH - Cambogia 2
LC - Santa Lucia 2
LK - Sri Lanka 2
MD - Moldavia 2
MM - Myanmar 2
MR - Mauritania 2
MV - Maldive 2
Totale 14.218
Salva come PNG Salva come JPEG
Città #
Amsterdam 1.871
Council Bluffs 740
Ashburn 528
Singapore 490
Cotonou 471
San Jose 316
Lauterbourg 315
Moscow 186
New York 165
St Louis 147
Los Angeles 117
Ho Chi Minh City 115
Hong Kong 98
Beijing 94
Columbus 94
Falkenstein 89
Santa Clara 77
Hanoi 75
Orem 73
São Paulo 70
Dublin 59
Tianjin 59
Atlanta 45
Buffalo 44
Guangzhou 40
Toronto 39
Houston 35
Warsaw 34
Brooklyn 33
Denver 33
Chicago 32
Dallas 32
Jacksonville 32
Chennai 28
Milan 28
Phoenix 28
Johannesburg 26
Montreal 26
Shanghai 24
Hangzhou 22
Mexico City 22
Rome 22
Poplar 19
Tokyo 19
Rio de Janeiro 18
Stockholm 17
Manchester 16
Naples 16
Las Vegas 15
Nairobi 15
Philadelphia 15
Da Nang 14
New Delhi 13
Quito 13
Shenzhen 13
Turin 13
Detroit 12
Querétaro 12
Baku 11
Kingston 11
Minneapolis 11
Mumbai 11
Amman 10
Baghdad 10
Charlotte 10
Haiphong 10
London 10
Medan 10
Milwaukee 10
Newark 10
Asunción 9
Bridgetown 9
Cape Town 9
Jakarta 9
Louisville 9
Miami 9
Nuremberg 9
Pittsburgh 9
Richmond 9
Washington 9
Chandler 8
Cincinnati 8
Erbil 8
Florence 8
Frankfurt am Main 8
La Plata 8
Lima 8
Olive Branch 8
Riyadh 8
Santiago 8
Seattle 8
Tashkent 8
Virginia Beach 8
Ankara 7
Belgrade 7
Boston 7
Campinas 7
Dhaka 7
Guayaquil 7
Hefei 7
Totale 7.481
Salva come PNG Salva come JPEG
Nome #
Circulating angiopoietin-like protein 2 levels are associated with decreased renal function in HIV+ subjects on cART: A potential marker of kidney disease 1.952
Coinfection with other respiratory pathogens in COVID-19 patients 101
Seroprevalence of SARS-CoV-2 among Workers in Northern Italy 81
A noma case report: A warning message from Northern Uganda 77
Post-tuberculosis lung disease: a guide for clinicians 76
Risk for SARS-CoV-2 Infection in Healthcare Workers, Turin, Italy 76
HCV NS3 naturally occurring variants in HIV/HCV coinfected DAA-naïve patients: consideration for HCV genotyping resistance testing 75
A Novel HPLC-MS/MS Method for the Intracellular Quantification of the Active Triphosphate Metabolite of Remdesivir: GS-443902 72
Long-term outcomes of the global tuberculosis and COVID-19 co-infection cohort 66
Risk of Reactivation of Latent Tuberculosis in Psoriasis Patients on Biologic Therapies: A Retrospective Cohort from a Tertiary Care Centre in Northern Italy 65
Pharmacogenetics-based Schedule Adjustment of Unboosted Atazanavir-based Regimens: 48 Weeks Results of Reyagen a Randomized and Controlled Pilot Study - PE10/14 62
Knowledge of Sexually Transmitted Infections and HIV among People Living with HIV: Should We Be Concerned? 62
Antiretroviral Drug Penetration into the CNS Compartment 62
Heart failure in patients with human immunodeficiency virus: a review of the literature 62
Development and validation of a useful HPLC-UV method for quantification of total and phosphorylated-ribavirin in blood and erythrocytes of HCV+ patients 61
Ceftriaxone cerebrospinal fluid levels in adult patients with meningoencephalitis 60
A reduced dose of darunavir/ritonavir is effective in PI-experienced HIV-infected patients 59
Alzheimer Dementia in People Living With HIV 58
Evaluation of coronary features of HIV patients presenting with ACS: The CUORE, a multicenter study 58
A review of the potential mechanisms of neuronal toxicity associated with antiretroviral drugs 57
Parietal resting-state EEG alpha source connectivity is associated with subcortical white matter lesions in HIV-positive people 57
Prognostic indicators for recurrent thrombotic events in HIV-infected patients with acute coronary syndromes: use of registry data from 12 sites in Europe, South Africa and the United States 57
Cardiovascular disease in HIV patients: from bench to bedside and backwards 56
A case of histological diagnosis of Toxoplasma gondii myositis in a person living with HIV 56
A UPLC-MS-MS method for the simultaneous quantification of first-line antituberculars in plasma and in PBMCs 56
Correction to: Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial (Journal of Translational Medicine, (2020), 18, 1, (405), 10.1186/s12967-020-02573-9) 56
A Machine Learning-Derived Cardiovascular Risk Score in People with HIV: The ML-ICONA Score 56
GREATER IMMUNOLOGICAL RECOVERY ASSOCIATED WITH ADDITIONAL ENFUVIRTIDE IN THE TREATMENT OF NAIVE HIV-INFECTED PATIENTS AT VERY ADVANCED DISEASE STAGES: 24-WEEK RESULTS OF A RANDOMIZED, CONTROLLED, PILOT STUDY 55
New UPLC-MS/MS method for simultaneous determination of dolutegravir, elvitegravir, rilpivirine and other 14 HIV drugs in human plasma 55
Pharmacokinetic of caspofungin in patients with invasive candidiasis 54
Convalescent or standard plasma versus standard of care in the treatment of COVID-19 patients with respiratory impairment: short and long-term effects. A three-arm randomized controlled clinical trial 54
Assessing ChatGPT's Potential in HIV Prevention Communication: A Comprehensive Evaluation of Accuracy, Completeness, and Inclusivity 54
Predictors of incomplete viral response and virologic failure in patients with acute and early HIV infection. Results of Italian Network of ACuTe HIV InfectiON (INACTION) cohort 54
Elimination half-life may explain the relative efficacy of boceprevir and telaprevir in the treatment of hepatitis C virus genotype 1 54
Incidence and clinical features of stroke in HIV patients in HAART era: a meta-analysis 53
Anti-CD20 antibody therapy for B-cell lymphomas 53
Intrathecal production of anti-EBV Viral Capsid Antigen IgG is associated with Neurocognition and tau pathology in people with HIV 53
In-hospital and long-term outcomes of HIV-positive patients undergoing PCI according to kind of stent: a meta-analysis 52
A meta-analysis investigating incidence and features of stroke in HIV-infected patients in the highly active antiretroviral therapy era 52
Ageing with HIV: a multidisciplinary review 52
Cardiac dysfunction in pauci symptomatic human immunodeficiency virus patients: a meta-analysis in the highly active antiretroviral therapy era 51
Pharmacokinetics of the Dual NRTI- and Protease Inhibitor-sparing Regimen Raltegravir plus Nevirapine in HIV-1+ Patients 50
Comparative safety and efficacy of statins for primary prevention in human immunodeficiency virus-positive patients: a systematic review and meta-analysis 49
Drugs for treating infections caused by non-tubercular mycobacteria: a narrative review from the study group on mycobacteria of the Italian Society of Infectious Diseases and Tropical Medicine 49
Prevalence and predictors of long corrected QT interval in HIV-positive patients: a multicenter study 48
Cerebral white matter Hyperintensities in HIV–positive patients 48
18-fluorodeoxyglucose positron emission tomography (FDG-PET) in patients with non-tuberculous mycobacterial infections 48
A pharmacogenetic study in HIV-infected patients treated with ritonavir: hematological and cardiovascular disease risk analysis 48
Cognitive Rehabilitation Treatment in HIV/AIDS patients with Asymptomatic Neurocognitive Impairment (ANI) and Mild Neurocognitive Disorders (MND) 48
Rifampicin and Isoniazid Maximal Concentrations are Below Efficacy-associated Thresholds in the Majority of Patients: Time to Increase the Doses? 48
A "Tinea" immune reconstitution inflammatory syndrome in a HIV-positive patient starting combination antiretroviral treatment 47
High prevalence at computed coronary tomography of non-calcified plaques in asymptomatic HIV patients treated with HAART: A meta-analysis 47
Correlations between cerebrospinal fluid biomarkers, neurocognitive tests, and resting-state electroencephalography (rsEEG) in patients with HIV-associated neurocognitive disorders 47
Pharmacogenetics-based Schedule Adjustment of Unboosted Atazanavir Associated with Tenofovir/Emtricitabine: A Randomized Controlled Study (REYAGEN) 47
Therapeutic Drug Monitoring of Boosted Protease Inhibitors and 48-week Risk of Virological Failure 47
HIV Infection and Primary Prevention of Cardiovascular Disease: Lights and Shadows in the HAART Era 46
Influence of efavirenz and 8-hydroxy-efavirenz plasma levels on cognition and central nervous system side effects 46
Serum Trimethylamine-N-oxide Concentrations in People Living with HIV and the Effect of Probiotics Supplementation 46
Neurosymptomatic HIV-1 CSF escape is associated with replication in CNS T cells and inflammation 46
Dolutegravir is not associated with weight gain in antiretroviral therapy experienced geriatric patients living with HIV 46
Transient plasma viral rebound after SARS-CoV-2 vaccination in an exceptional HIV-1 elite controller woman 46
A LC-MS method to quantify tenofovir urinary concentrations in treated patients 46
Outcomes of Drug Interactions Between Antiretrovirals and Co-Medications, Including Over-the-Counter Drugs: A Real-World Study 45
A filter-based cross-sectional analysis of an HIV-positive, HAART-treated cohort in rural Burundi: pharmacokinetics, pharmacogenetics and viral load 45
Symptomatic and Asymptomatic Neurocognitive Impairment, ART Adherence and HIV Control: A 4-Year Observational Study 45
Clinical Treatment Options and Randomized Clinical Trials for Neurocognitive Complications of HIV Infection: Combination Antiretroviral Therapy, Central Nervous System Penetration Effectiveness, and Adjuvants 45
Diagnostic SARS-CoV-2 Cycle Threshold Value Predicts Disease Severity, Survival, and Six-Month Sequelae in COVID-19 Symptomatic Patients 44
Ritonavir-dependent fluconazole boosting of nelfinavir: a report of three cases 44
Plasma concentration of boosted and unboosted Atazanavir are predicted by 63396C>T SNP in the PXR gene 44
Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19 44
Single-nucleotide polymorphism PXR 7635G>A influences plasma concentrations of Efavirenz in CYP2B6 516G>T carriers 44
Intracellular Accumulation of Tipranavir/Ritonavir 44
Single-nucleotide polymorphisms ABCB1 3435C>T, 1236C>T and CYP2B6 516G>T influence plasma concentrations of Efavirenz (EFV) 44
Intracellular antiviral activity of low-dose ritonavir in boosted protease inhibitors regimens 44
A(H1N1)pdm09 hemagglutinin D222G and D222N variants are frequently harbored by patients requiring extracorporeal membrane oxygenation and advanced respiratory assistance for severe A(H1N1)pdm09 infection 44
Serum and CSF biomarkers in asymptomatic patients during primary HIV infection: a randomized study 43
The role of bacteria and viruses in Behçet syndrome: Should we move towards new paradigms? 43
Pharmacogenetics of Antiretrovirals' Penetrations into Cerebrospinal Fluid 43
Diagnosis of HIV associated Neurocognitive Disorders in Italian cohort: comparison of Clinical Rating and Deficit Score 43
Association between tight junction proteins and cognitive performance in untreated persons with HIV 43
Staphylococcus aureus meticillino-resistente 43
Patterns of Cerebrospinal Fluid Alzheimer’s Dementia Biomarkers in People Living with HIV: Cross-Sectional Study on Associated Factors According to Viral Control, Neurological Confounders and Neurocognition 42
Inflammation and intracellular exposure of dolutegravir, darunavir, tenofovir and emtricitabine in people living with HIV 42
Case Report: Atypical Cutaneous Presentation of Human T-cell Lymphotropic Virus Type 1-Related Adult T-cell Lymphoma 42
Determinants of SARS-CoV-2 Contagiousness in Household Contacts of Symptomatic Adult Index Cases 42
BCGitis after Bacille Calmette-Guerin intravesical administration from two referral centers: clinical characteristics and risk factors 42
A population pharmacokinetic model confirms an association between a pregnane-X-receptor (PXR) polymorphism and unboosted atazanavir clearance 42
Prescription habits and drugs accessibility for the treatment of non-tuberculous mycobacteria infections in Italy: a multicentric survey from the IRENE study group 42
Primary HIV infection features colonic damage and neutrophil inflammation yet containment of microbial translocation 41
Clinical pharmacology of complex regiment of antiretroviral therapy including Etravirine, Maraviroc and Raltégravir 41
Plasma, Intracellular and Lymph node Antiretroviral Concentrations and HIV DNA Change During Primary HIV Infection: Results from the INACTION P25 Study 41
Pharmacokinetic of doxorubicin during chemotherapy in HIV patients affected by Hodgkin disease and Non- Hodgkin’s Lymphoma: the PKCT study 41
Therapeutic drug monitoring of boosted PIs in HIV-positive patients: undetectable plasma concentrations and risk of virological failure 40
Changes in Cerebrospinal Fluid, Liver and Intima-media-thickness Biomarkers in Patients with HIV-associated Neurocognitive Disorders Randomized to a Less Neurotoxic Treatment Regimen 40
Living with HIV and Getting Vaccinated: A Narrative Review 40
Cognitive Rehabilitation Protocol in HIV-AIDS Outpatients with ANI and MND Results and Clinical Applicability 40
CNS-Targeted Antiretroviral Strategies: When Are They Needed and What to Choose 40
HIV associated neurocognitive disorders (hand) assessment: the sensitivity and specificity of verbal memory span and frontal assessment battery (FAB) 40
Pharmacokinetics of 400 mg of raltegravir once daily in combination with atazanavir/ritonavir plus two nucleoside/nucleotide reverse transcriptase inhibitors 39
Dual β-lactams for the treatment of Mycobacterium abscessus: a review of the evidence and a call to act against an antibiotic nightmare 39
Totale 6.985
Salva come PNG Salva come JPEG
Categoria #
all - tutte 52.176
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 52.176
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202235 0 0 6 5 1 0 0 0 4 4 7 8
2022/202397 9 7 9 0 4 7 2 3 53 0 3 0
2023/202429 4 3 1 0 5 0 6 0 0 0 2 8
2024/202581 0 0 4 1 0 2 7 11 22 18 3 13
2025/202612.932 8 12 27 1.793 1.798 993 1.582 1.926 2.575 843 750 625
2026/20271.406 1.401 5 0 0 0 0 0 0 0 0 0 0
Totale 14.636